President Donald Trump said on Thursday that he plans to lower the price of Ozempic, signaling a sharp move in his administration’s broader campaign to reduce prescription drug costs.
Speaking at a White House event focused on fertility treatments and drug pricing, Trump identified Ozempic as the drug he intended to target, saying “they’ll be much lower.” While the list price for a month’s supply currently hovers around $1,000, he floated a target price of $150 during his remarks.
Novo Nordisk, the maker of Ozempic (and its weight-loss variant Wegovy), confirmed ongoing talks with the administration over pricing but declined to directly comment on Trump’s figure. The company has already been offering Ozempic at $499 per month to qualified cash-paying patients in the U.S. through its direct distribution programs.
Health officials acknowledged that price negotiations for GLP-1 drugs like Ozempic were not finalized, noting that such changes would occur under existing frameworks for drug-pricing reforms.
